Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02849899
Other study ID # N/2015/70
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date October 26, 2018
Est. completion date December 2024

Study information

Verified date July 2022
Source Centre Hospitalier Universitaire de Besancon
Contact Emilie Gaiffe, Dr.
Phone 0381218824
Email egaiffe@chu-besancon.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Post-transplant diabetes affects 15 to 20% of renal transplant patients and contributes to increased morbidity and reduced survival of transplants and patients. Corticosteroids, anti-calcineurin and mammilian Target OF Rapamycin (mTOR) inhibitors have a major diabetogenic impact and greatly contribute to the increase in diabetes prevalence after transplantation. There are to date few studies concerning the pharmacological prevention of post-transplant diabetes. Hecking et al. have recently reported that a short treatment with insulin, administered immediately after transplantation, reduce the incidence of de novo diabetes one-year post-transplant. This study included 50 renal transplant patients and showed that a three months treatment of (Neutral Protamine Hagedorn) NPH insulin decreased HbA1c. The occurrence of diabetes, a secondary end-point, was reduced by 73% in the treated group. No further pharmacological strategy has been developed to date. Relevant experimental evidences suggest that gliptins could be used in the pharmacological prevention of post-transplant diabetes. These drugs are inhibitors of dipeptidyl peptidase-4 (DPP-4), which inactivates the incretins, the glucagon-like peptide-1 (GLP-1) and the gastric inhibitory polypeptide (GIP). DPP-4 inhibition causes an increase in the GLP-1 and GIP concentrations which induce insulin secretion and inhibition of glucagon secretion. The gliptins are approved for the treatment of type 2 diabetes. Beyond the effects on blood glucose, gliptins have pleiotropic effects including a protective effect on β cells and anti-inflammatory effect. The additional cost associated with new-onset diabetes after transplantation could be also significantly reduced by efficient prevention. A US study found that, for the period between 1994 and 1998, a newly diagnosed diabetic patient has cost $21,500 of medical expenses 2 years after transplantation. Moreover, transplantation resulting in one of the best increases of patients' quality of life, its estimate is essential in the treatment evaluation of this population.


Recruitment information / eligibility

Status Recruiting
Enrollment 186
Est. completion date December 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Major Patients (18 year old or older) - Signature of informed consent - Affiliation to a French social security or receiving such a scheme - Patient receiving a first kidney transplant - Patients considered at high risk of developing posttransplant diabetes having at least 2 of the 3 following criteria: Age> 50 years; BMI greater than 30 kg/m²; Direct Family history of type 2 diabetes - Patients who can receive immunosuppressive therapy including tacrolimus, mycophenolic acid and steroids - Patients in whom the cessation of steroids may be considered at the latest at Month 3 post-transplant Exclusion Criteria: - Legal disability or limited legal capacity - Topic unlikely to cooperate in the study and / or low early cooperation by the investigator - Patient without health insurance - Pregnancy - Patient in the period of exclusion of another study or under the "national register of volunteers." - Inability to understand the reasons for the study; psychiatric disorders judged by the investigator to be incompatible with the inclusion in the study - Active infection - Infection with Hepatitis C virus - A history of diabetes - Multi-Organ Transplantation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vildagliptin
Galvus is prescribed as recommended by the marketing authorization. In adults, the recommended dose of Galvus is 100 mg per day (one tablet in the morning and another in the evening). In patients with moderate or severe kidney problems, the recommended dose is 50 mg once daily (one tablet in the morning). Patients with creatinine clearance greater than 50 ml/min the vildalgliptin dose will be 100 mg/day. For those whose clearance is less than 50 ml/min, the daily dose is 50 mg. The creatinine clearance will be measured each week. The treatment duration will be 3 months, divided into 2 months of complete treatment and one month of cessation treatment with half dose of vildagliptin.
Placebo
The placebo is the same as Galvus (packaging, shape, color, registration) but will contain only excipient. The given dose will also be identical.

Locations

Country Name City State
France CHU de Besançon Besançon

Sponsors (10)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Besancon Amiens University Hospital, Centre Hospitalier Universitaire de Nice, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne, Rennes University Hospital, Tenon Hospital, Paris, University Hospital, Brest, University Hospital, Lille, University Hospital, Strasbourg, France, University Hospital, Tours

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diabetes event The primary endpoint is the proportion of diabetic patients 1 year after transplantation.
Diabetic patients are defined as one of the following proposals:
Patients receiving a diabetic treatment
Patients have a fasting glucose above 7 mmol/l
Patients with an abnormal oral glucose tolerance test (OGTT)
1 year
Secondary Glycemic control The criteria for secondary assessments are abnormal blood glucose measured by: the glycated hemoglobin (HbA1c) 3 months, 6 months and 12 months after transplantation. 3, 6 and 12 months
Secondary Acute rejection, infections, graft and patient survival The occurrence of acute rejection, infection, graft loss and patient death 3 months, 6 months and 12 months after transplantation. 3, 6 and 12 months
Secondary The health-related quality of life improvement The health-related quality of life (ReTRANSQOL questionnaire), 3 months, 6 months and 12 months after transplantation. 3, 6 and 12 months
Secondary The cost-effectiveness ratio The cost-effectiveness of prevention of diabetes with vildagliptin 1 year
See also
  Status Clinical Trial Phase
Completed NCT05594446 - Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
Completed NCT03975309 - DHS MIND Metabolomics
Completed NCT01855399 - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes N/A
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05007990 - Caregiving Networks Across Disease Context and the Life Course
Active, not recruiting NCT04420936 - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program N/A
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT04903496 - Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
Completed NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects Phase 1
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT03390179 - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Recruiting NCT05294822 - Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes N/A
Completed NCT04427982 - Dance and Diabetes/Prediabetes Self-Management N/A
Completed NCT02356848 - STEP UP to Avert Amputation in Diabetes N/A
Completed NCT03292185 - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects Phase 1
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4